Alkermes Q2 2026 earnings call transcript
ALKS•Q2 2026 earnings call highlights
- Alkermes discussed Q2 2026 results on an earnings call attended by CEO Richard Pops, CFO Joshua Reed, CCO Todd Nichols, COO and incoming CEO Blair Jackson.
- Pops said Blair Jackson becomes CEO next week; Alkermes will keep Pops as chairman.
- Management highlighted orexin portfolio momentum: phase 3 alixorexton narcolepsy studies enrolling, completion expected next year; Vibrance-3 idiopathic hypersomnia phase 2 completes in Q4.
- Blair Jackson said ALKS 7290 adult ADHD phase 1b topline data are expected by end-Q3; ALKS 4510 fatigue phase 2 planned later this year.
- Reed reported Q2 total revenue of $496 million; Q3 revenue guided to $450-$470 million, adjusted EBITDA to $80-$100 million; cash and investments about $690 million.
Related News
NRG Energy Inc <NRG.N>: UBS Cuts Target Price to $216 From $221
NRG•
John Marshall Bancorp posts investor presentation outlining growth strategy, financial highlights
JMSB•
